Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:1528-1536
Published online before print March 19, 2007, doi: 10.1161/CIRCULATIONAHA.106.649939
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
115/12/1528    most recent
CIRCULATIONAHA.106.649939v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sabatine, M. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sabatine, M. S.
Related Collections
Right arrow Chronic ischemic heart disease

(Circulation. 2007;115:1528-1536.)
© 2007 American Heart Association, Inc.


Coronary Heart Disease

Prognostic Significance of the Centers for Disease Control/American Heart Association High-Sensitivity C-Reactive Protein Cut Points for Cardiovascular and Other Outcomes in Patients With Stable Coronary Artery Disease

Marc S. Sabatine, MD, MPH; David A. Morrow, MD, MPH; Kathleen A. Jablonski, PhD; Madeline Murguia Rice, PhD; J. Wayne Warnica, MD; Michael J. Domanski, MD; Judith Hsia, MD; Bernard J. Gersh, MD; Nader Rifai, PhD; Paul M Ridker, MD; Marc A. Pfeffer, MD, PhD; Eugene Braunwald, MD, for the PEACE Investigators

From the Cardiovascular Division, Brigham and Women’s Hospital and Department of Medicine, Harvard Medical School, Boston, Mass (M.S.S., D.A.M., P.M.R., M.A.P., E.B.); George Washington University, Rockville, Md, and Washington, DC (K.A.J., M.M.R., J.H.); Department of Cardiac Sciences, University of Calgary, Calgary, Alberta, Canada (J.W.W.); National Heart, Lung, and Blood Institute, Bethesda, Md (M.J.D.); Mayo Clinic Foundation, Rochester, Minn (B.J.G.); and Department of Laboratory Medicine and Pathology, Children’s Hospital, Boston, Mass (N.R.).

Correspondence to Marc S. Sabatine, MD, MPH, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail msabatine{at}partners.org

Received July 6, 2006; accepted January 5, 2007.

Background— Data supporting the prognostic significance of high-sensitivity C-reactive protein (hs-CRP) are derived largely from individuals with no overt coronary artery disease or from patients with acute coronary syndromes. In contrast, the ability of hs-CRP to predict outcomes in patients with stable coronary artery disease and the prognostic significance of the Centers for Disease Control/American Heart Association hs-CRP cut points in such a population remain relatively unexplored.

Methods and Results— We measured hs-CRP in 3771 patients with stable coronary artery disease from the Prevention of Events With Angiotensin-Converting Enzyme Inhibition (PEACE) trial, a randomized placebo-controlled trial of the angiotensin-converting enzyme inhibitor trandolapril. Patients were followed up for a median of 4.8 years for cardiovascular death, myocardial infarction, or stroke, as well as new heart failure and diabetes. After adjustment for baseline characteristics and treatments, higher hs-CRP levels, even >1 mg/L, were associated with a significantly greater risk of cardiovascular death, myocardial infarction, or stroke (hs-CRP 1 to 3 mg/L: adjusted hazard ratio, 1.39; 95% CI, 1.06 to 1.81; P=0.016; hs-CRP >3 mg/L: adjusted hazard ratio, 1.52; 95% CI, 1.15 to 2.02; P=0.003). Similarly, elevated hs-CRP levels were an independent predictor of new heart failure (adjusted P<0.001 for trend) and new diabetes (adjusted P<0.001 for trend). There were no significant interactions between hs-CRP levels and the effects of trandolapril on any of the above outcomes.

Conclusions— In stable coronary artery disease, an elevated hs-CRP level, even >1 mg/L, is a significant predictor of adverse cardiovascular events independently of baseline characteristics and treatments. An elevated hs-CRP does not appear to identify patients with stable coronary artery disease and preserved ejection fraction who derive particular benefit from angiotensin-converting enzyme inhibition.


 

CLINICAL PERSPECTIVE




This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
E. A. Van Vre, H. Bult, V. Y. Hoymans, V. F.I. Van Tendeloo, C. J. Vrints, and J. M. Bosmans
Human C-Reactive Protein Activates Monocyte-Derived Dendritic Cells and Induces Dendritic Cell-Mediated T-Cell Activation
Arterioscler. Thromb. Vasc. Biol., March 1, 2008; 28(3): 511 - 518.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
P. A. Kavsak, D. T. Ko, A. M. Newman, G. E. Palomaki, V. Lustig, A. R. MacRae, and A. S. Jaffe
Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide
Clin. Chem., December 1, 2007; 53(12): 2112 - 2118.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
M. Kivimaki, D. A. Lawlor, G. D. Smith, C. Eklund, M. Hurme, T. Lehtimaki, J. S. A. Viikari, and O. T. Raitakari
Variants in the CRP Gene as a Measure of Lifelong Differences in Average C-Reactive Protein Levels: The Cardiovascular Risk in Young Finns Study, 1980 2001
Am. J. Epidemiol., October 1, 2007; 166(7): 760 - 764.
[Abstract] [Full Text] [PDF]